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Tuberculosis (TB) ranks alongside HIV as the leading cause of death worldwide, killing
1.5 million people in 2014. Traditional laboratory techniques do not provide sufficiently
rapid results to inform clinicians on appropriate treatment, especially in the face of
increasingly prevalent drug-resistant TB. Rapid molecular methods such as PCR and LAMP
are vital tools in the fight against TB, however, rapid advances in next generation sequenc-
ing (NGS) technology are allowing increasingly rapid and accurate sequencing of entire bac-
terial genomes at ever decreasing cost, providing unprecedented depth of information.
These advances mean NGS stands to revolutionise the diagnosis and epidemiological study
of Mycobacterium tuberculosis infection. This review focuses on current applications of NGS
for TB diagnosis including sequencing cultured isolates to predict drug resistance and,
more desirably, direct diagnostic metagenomic sequencing of clinical samples. Also dis-
cussed is the potential impact of NGS on the epidemiological study of TB and some of
the key challenges that need to be overcome to enable this promising technology to be
translated into routine use.
 2016 Asian-African Society for Mycobacteriology. Production and hosting by Elsevier Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
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Introduction carefully screened for, hence sensitive methods which canTuberculosis (TB) remains an important global health problem
with an estimated 9.6 million TB cases and 1.5 million associ-
ated deaths worldwide in 2014 [1]. Improved diagnostics and
ongoing research are central tenets to the World Health
Organisation (WHO) End TB Strategy and the Foundation for
Innovative New Diagnostics (FIND) Strategy for Tuberculosis
and Lower Respiratory Tract Infections [2,3]. Of significant
concern is the rapidly increasing prevalence of multi-drug
resistant (MDR-TB, TB resistant to at least rifampicin and iso-
niazid) and extensively drug resistant TB (XDR-TB, MDR-TB
with additional resistance to any fluoroquinolone and one
second line injectable agent (amikacin/kanamycin/capreomy
cin). Annually there are 500,000 new MDR-TB cases including
7.4–12% XDR-TB. Current culture and PCR based diagnostics
tests for XDR-TB are not sufficiently rapid and/or accurate
to effectively manage patients [2,3]. Whilst molecular meth-
ods such as Xpert MTB/RIF (Cephid, U.S.) have provided sig-
nificant steps forward in achieving the goals set out by the
WHO and FIND, next generation sequencing (NGS)
approaches hold great promise for the future diagnosis and
management of TB on an individual and population basis
[4,5].
This review will outline how NGS, through fast and accu-
rate whole genome sequencing (WGS) and/or shotgun
metagenomics sequencing (SMS), holds the potential to trans-
form the diagnosis and management of TB both for the indi-
vidual patient and as an epidemiological tool.
The MTB genome and drug resistance
Mycobacterium tuberculosis (MTB) belongs to a complex of
related mycobacteria species (M. tuberculosis complex or
MTBC) including M. tuberculosis, Mycobacterium africanum,
Mycobacterium bovis, Mycobacterium microti, Mycobacterium
canetti, Mycobacterium pinnipedii and Mycobacterium caprae [6].
The MTB genome was first sequenced in 1998 from the
H37Rv strain and comprises of around 4.4 million base pairs,
codes for around 4000 genes (many of which are involved in
lipogenesis and lipolysis) and has a high (65.6%) guanine
and cytosine (G + C) content [7]. It has long been thought that
there is minimal genetic variation between MTB strains, and
what variation exists is of minimal clinical significance.
WGS has played an important role in challenging this dogma,
suggesting that there is a greater than previously appreciated
genomic variance between MTB strains which can give rise to
clinically significant phenotypic differences (for example the
increased virulence observed in the Beijing family of strains)
[8–13]. Unlike other bacterial species, drug resistance in MTB
is largely attributable to small genetic events such as single
nucleotide polymorphisms (SNPs) as opposed to other
sources of variation (i.e. horizontal transfer by mobile genetic
elements such as plasmids) [14]. As such, novel mutations
which could potentially confer drug resistance need to belook at the whole MTB genome are desirable for understand-
ing the mechanisms of drug resistance and the evolution of
drug resistance over time.
There are a number of established and well characterised
drug resistance mechanisms within the MTB genome, mainly
arising through point mutations in genes encoding for the tar-
get protein of the drug, or proteins required for drug activa-
tion. Rifampicin resistance commonly arises through
mutations in an 81 base pair region in the rpoB gene known
as the rifampicin resistance determining region (RRDR) – the
target of the Xpert MTP/Rif assay. The rpoB gene codes for
the b-subunit of RNA polymerase which is the target of rifam-
picin. Mutations in this region account for approximately 96%
of phenotypic rifampicin resistance and as more than 90% of
rifampicin resistant strains are also resistant to isoniazid,
rifampicin resistance is used as a surrogate marker for
MDR-TB [15,16]. Isoniazid resistance arises through muta-
tions in catalase peroxidase encoding genes (katG) (which
prevents activation of isoniazid resulting in high level resis-
tance) or mutations in inhA, the target of the activated form
of isoniazid (low level resistance). The majority of pyrazi-
namide resistance is conferred through the prevention of
drug activation through a diverse set of mutations in the pncA
gene and ethambutol resistance through over expression of
the target protein (Emb) or mutations in the embB gene in
the majority of resistant strains. Mutations associated with
resistance to second line anti-TB agents resulting in XDR-TB
are also well described. The majority of fluoroquinolone
resistance results through mutations in subunits A and B of
DNA gyrase (topoisomerase II) – the target protein of the
fluoroquinolones, and resistance to the second line injectable
agents amikacin and kanamycin resulting from 16s rRNA
mutations [17,18]. Predictable and well characterised muta-
tions such as these make them targets for molecular based
tests, however a clear mechanism of drug resistance is not
established in 10–40% of resistant strains. The genomic basis
of resistance in these cases are likely to be SNPs occurring
outside established resistance genes and the mechanism of
resistance uncertain [19]. WGS can be used to accurately
detect these SNPs [20] and can help define the mechanism
of resistance and importantly allow development over time
of a reference library of resistance mutations against which
an index strain can be compared.
Current molecular methods in TB diagnostics and
molecular epidemiology
Sputum microscopy and microbiological culture is the ‘gold-
standard’ for the diagnosis of TB. Whilst direct microscopy
offers the advantages of being a rapid and inexpensive test
with high specificity for TB (in endemic areas), the method
suffers from low (and variable) sensitivity (20–60%) [21].
Depending on the setting and resources available, samples
will be cultured in liquid medium over several weeks or on
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(up to 12 weeks) [22]. Liquid culture platforms, for example
the Mycobacterium Growth Indicator Tube (MGIT) system
(Becton-Dickenson, US) have been able to reduce the time to
positivity compared to solid media from 21 days to 6–12 days
[23,24]. Direct nucleic acid amplification tests (NAAT) are play-
ing an increasingly important role in the diagnosis of TB, with
the WHO endorsing the Xpert MTB/RIF test in 2010. The
Xpert MTB/Rif assay is a sample-in-answer-out test run on
the GeneXpert systemwhich extracts nucleic acid, amplifies
the RRDR of the MTBC, probes for mutations using molecular
beacons and analyses using the GeneXpert software [25].
This system can provide identification of the presence of
MTBC as well as identifying potential resistance to rifampicin
at or near the point-of-care with 2 h with 89% (85–92%) sensi-
tivity and 99% (98–99%) specificity [4,26–28]. Loop mediated
isothermal amplification (LAMP) is an alternative NAAT – an
isothermal amplification method using 4 primers to target 6
distinct DNA sequences [29]. The key advantage of LAMP over
the Xpert MTB/RIF assay is that there is no requirement for a
thermal-cycler. A recent meta-analysis suggests a pooled sen-
sitivity of 93% (92–95%) and specificity of 94% (92–95%) com-
pared to culture, however there was a high degree of
heterogeneity between studies (I2 > 85%) [30] .
Methods currently used for species/strain typing in molec-
ular epidemiology of MTBC include IS6110 restriction frag-
ment length polymorphisms (RFLP), spoligotyping, variable-
number-tandem repeat (VNTR) and multispacer sequence
typing. IS6110 is a mobile genetic element found in MTBC
and is found in multiple copies in the MTB genome, the num-
ber of copies varies between strains so can be used as a tool to
discriminate between strains of MTB [31–33]. Spoligotyping
(spacer-oligotyping) utilises the DNA polymorphism within
the Direct Repeat (DR) locus of the MTB genome. The DR locus
consists of 36 bp DRs with variable ‘spacer’ regions inter-
spersed between them. Species within the MTBC vary in the
number of DR repeats and presence of specific variable
spacers allowing some separation of species [34]. Similarly,
VNTR is a molecular typing tool based upon 24 loci within
the MTB genome which contain variable numbers of tandem
repeats called mycobacterial interspersed repetitive units
(MIRU-VNTRs). The technique uses PCR primers designed to
amplify these with subsequent determination of the size of
PCR product (amplicon) using gel electrophoresis which can
be used in turn to determine the number of MIRU-VNTR
copies [35]. Whilst these tools are useful in epidemiological
studies, there are some disadvantages, for example IS6110
RFLP requires a high volume of starting DNA and whilst
spoligotyping can differentiate species within the MTBC, it
lacks the resolution to resolve closely related strains of
MTB. These techniques have been reviewed in more detail
elsewhere [9,36,37].Next generation sequencing
The past decade has seen a revolution in the way in which
genetic sequencing is performed. The original chain termina-
tion method of sequencing deoxyribonucleic acid (DNA)
described by Sanger has been surpassed by NGS technology[38,39]. NGS can provide whole bacterial genome sequences
in a short timeframe (hours–days), at a relatively low cost
and, increasingly, without the need for culture [40]. There
are a number of different NGS platforms available which
can be broadly classified into those which result in DNA
sequences which are relatively short (<1000 base pairs), so-
called ‘short reads’, and those providing longer DNA
sequences (long reads >5000 base pair average) both of which
offer theoretical advantages. The depth of information pro-
vided through NGS has the potential to improve the speed
and accuracy of MDR/XDR-TB diagnosis, and improve our
understanding the epidemiology of TB.
NGS technologies produce thousands-millions of reads of
varying length, which can then be reassembled into longer
or whole genome sequences using bioinformatics. The next
generation sequencing technologies which provide long
sequence reads include PacBio single molecule-real time
(SMRT), (Pacific Biosciences, US) and MinION nanopore
sequencing (Oxford Nanopore Technologies, UK). Sequencing
by synthesis (Illumina Inc., US) and Ion Torrent semi-
conductor sequencing (ThermoFisher Scientific, US) both pro-
vide short read lengths. Illumina are currently the NGS mar-
ket leaders, offering high accuracy (99%) short-read (6300
bases) sequence data. Current infectious diseases applica-
tions include species identification, isolate sequencing and
typing for public health surveillance [41,42], for example,
the use of WGS for Salmonella surveillance [43,44], outbreak
surveillance and transmission studies (for example monitor-
ing methicillin resistant Staphylococcus aureus outbreaks)
[45,46]. PacBio provides long read sequencing and has been
used extensively in microbiology research including
mycobacterial research [47–50]. The MinION platform offers
long read sequencing and is a highly transportable sequenc-
ing device at a much reduced cost (1000 USD) can be plugged
into a laptop computer and has been used for a number of
epidemiology and diagnostic applications including the
recent Ebola outbreak in West Africa and for the diagnosis
of pathogens and antimicrobial resistance directly from urine
[51,52].
Whilst NGS is a powerful tool, it does have associated chal-
lenges which need consideration. One challenge is being able
to determine whether differences between sequences occur
because of sequence variance or because of sequencing error.
Error rates are different for the different sequencing technolo-
gies (e.g. indels, G/C bias, homopolymer errors) and types of
error are also different. In order to overcome this, multiple
reads of the same sequence are required (sequencing depth),
which can be compared to a reference dataset or used to gen-
erate consensus data for SNP calling (not possible if errors are
systematic). Also, genomic DNA contains repeat elements
which can be hundreds to thousands of base pairs in length.
Short reads are unable to ‘bridge’ these repeats and so a com-
plete genome cannot be assembled. Long reads can bridge
these repeat elements and can be de novo assembled relatively
easily, resulting in complete genomes [53,54].
Despite some challenges, the potential benefits NGS holds
over current methods for the diagnosis and epidemiological
monitoring of TB include time to diagnosis, depth of informa-
tion provided and convenience:
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(from weeks to hours) using NGS for TB diagnosis
directly from sputum or determining the antibiotic
resistance of an isolate [55,56].
2: The depth of information provided by NGS can be used
to identify whether there are multiple co-infecting
strains within the same individual (and has demon-
strated the presence of mixed strain infection in histor-
ical TB isolates [57,58]) and to help differentiate relapse
from re-infection [59]. Epidemiological information on
circulating strains, drug resistance and chains of trans-
mission can be collected in real-time.
3: Convenience: NGS has the potential to combine
diagnosis, drug resistance profiling and epidemiological
analysis into one tests [9].
NGS can be performed from isolates of MTB following
culture, or, directly from clinical isolates. The ability to detect
and characterise MTB directly from clinical samples holds the
greatest potential in terms of improving the management of
MTB but also presents the greatest challenge. The remainder
of this review will examine the current use of NGS in detect-
ing MTB from cultured isolates and directly from clinical
samples.
Whole genome sequencing from isolates
Several retrospective studies have looked into the role of WGS
in detecting drug resistant TB from cultured isolates and have
found a high level of genotypic-phenotypic concordance with
regards to antimicrobial susceptibility [55,56]. One study in
particular [56], developed a training set of 120 resistance
determining and 772 benign mutations and successfully
predicted susceptibility in 89.2% of 1552 validation-set
phenotypes (449 isolates phenotypically resistant to at least
one drug, 284 MDR-TB isolates and 3 XDR-TB isolates). This
level of concordance is promising suggesting a clear role for
WGS in predicting drug susceptibility in MTB, however fur-
ther study is required as the genetic basis for many phenotyp-
ically resistant strains is not fully understood. This gap in
knowledge was highlighted in one study comparing the sen-
sitivity of techniques for predicting antimicrobial resistance
from WGS, achieving 99.1% concordance with phenotypic
results for S. aureus but only 82.6% concordance for MTB [60].
Recent studies have examined the potential role of WGS in
informing the clinicalmanagement of TB [61,62]. One prospec-
tive study [61] has utilised the Ion Torrent system to explore
the role of WGS in informing the clinical management of
XDR-TB in 16 clinical specimens from 6 patients. The authors
demonstrated that resistance phenotype could, in most cases,
be reasonably predicted from the genome sequence and WGS
was useful in improving confidence in clinical decision mak-
ing. The authors point out that there is a need for consensus
agreement for genotype-phenotype standards. In order to help
address this issue, a number of databases have been set-up
containing information on mutations conferring drug
resistance such as TBDreamDB and MUBII-TB-DB [56,63–65].
One group has produced a collated database, containing
information on resistance to 11 anti-TB agents through 1325mutations and has developed a software tool, ‘TB profiler’, to
allow raw sequencing data to be screened and drug resistance
predicted in silico [66]. More recently a large, multi-centred
prospective study has begun to challenge some of the per-
ceived barriers to WGS by comparing real-time WGS of MTB
isolates from positive culture with traditional laboratory
workflow. The study was conducted across 8 laboratories in
Europe and North America with local sequencing (Illumina)
and centralised bioinformatics. The study demonstrated that
WGS predicted both species and phenotypic drug resistance
with 93% accuracy compared to traditional workflow with a
potential 7% cost improvement [67].
The role of WGS in investigating the transmission of TB is
the subject of much interest given the potential to be able to
differentiate between strains of TB that are indistinguishable
based on current molecular epidemiological techniques, so
providing a tool with improved resolution [68,69]. The princi-
pal is that mutations which arise in the MTB genome from
one individual will be passed onto all the other people that
are infected by the original host [36]. A recent systematic
review of the role of WGS in TB transmission studies revealed
that the use of WGS data to infer transmission and direction
of transmission of TB varies between studies and settings
[70]. One key area of difference was the use of SNP thresholds
to define transmission – the thresholds used for transmission
studies varied from 0 to 2 SNPs whilst others studies used
610. The authors point out that the particular SNP threshold
is context dependent with factors including the strain
diversity, within-host diversity, read quality and number of
amplification steps making comparisons across studies chal-
lenging. A further systematic review designed to examine
how WGS compared to conventional epidemiology (i.e. con-
tact tracing and current molecular methods) compared 12
studies. The study revealed that WGS had high sensitivity
(78.5–100%) compared to conventional epidemiological tools
and had a higher discriminatory power than conventional
genotyping to differentiate clusters of MTB strains [71].
Whole genome sequencing directly from clinical
samples
Given the need for reduced turnaround time to diagnosis and
rapid recognition of drug-resistance, one of the most
desirable applications of NGS is to be able to sequence patho-
gen DNA directly from clinical samples (shotgun metage-
nomics) without the need for time consuming culture. One
of the key challenges in achieving this goal is the need for a
sufficient proportion of pathogen DNA in the metagenome
in order to generate enough breadth and depth of coverage
of the pathogen genome. However, the numbers of MTBC in
clinical samples tends to be low (pauci-bacillary) meaning a
low ratio of pathogen:bacterial and pathogen:human DNA –
this is especially challenging in both the HIV population and
the paediatric population (from whom obtaining sputum
can be difficult) [72]. One study has demonstrated that SMS
can be applied directly to sputum samples which have under-
gone a relatively straightforward differential lysis and DNA
extraction process. The authors were able to correctly detect
and characterise MTB sequences in 7 out of 8 samples taken
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correctly identified to species/lineage/clade level providing
useful information, there was a high number of non-TB reads
in the sequencing data and both the breadth of coverage of
the H37Rv reference genome (0.002X to 0.7X) and the depth
of sequencing (1.2–1.9X) were too low to be able to confidently
predict resistance [73]. This study highlights the promising
potential for SMS in diagnosing TB but also the need for devel-
opment of enrichment processes which efficiently increases
the ratio of MTB:non-MTB (human, bacterial, viral, fungal)
DNA. A recent study describes one such pathogen specific
enrichment method that yields enough DNA for SMS directly
from clinical samples [74]. The enrichment process uses
custom designed RNA baits (SureSelectXT, Agilent, US) to
specifically capture MTB DNA from total DNA extracted from
sputum. When applied to clinical samples this method
improved the number of MTB reads from 0.3% in non-
enriched samples to 82% in enriched samples and the mean
depth of sequencing from 4.6x to 200x [74].Challenges
There are a number of key issues which make the translation
of NGS methods in under-resourced settings a challenge. NGS
hasn’t yet penetrated most low and middle income countries
(LMICs) where TB is most prevalent and until recently it
hasn’t been feasible to apply it to infectious diseases
diagnosis. Short-read highly multiplexed NGS is becoming
affordable (<$50 per bacterial genome) but waiting to batch
sufficient samples erodes the time saving advantage of this
approach. Also, the cost of the machines/maintenance, the
turnaround time for sequencing and the complexity of
the informatics make short-read technology unlikely to be
utilised for infectious diseases diagnostics in LMICs. Long-
read technologies have lower read-accuracy (by 5–10% for
single reads) but data analysis is easier. The PacBio RSII and
Sequel devices suffer many of the same disadvantages as
short-read sequencing devices but MinION sequencing
demonstrates great potential for infectious diseases diagnos-
tics in LMICs. A combination of portability, low capital cost
($1000 USD), no maintenance cost, automated rapid library
preparation (Voltrax) and sequencing and automated real-
time analysis makes MinION ideal for TB diagnosis (from cul-
ture for DST and/or directly from sputum) in LMICs. Cost per
flow cell ($500 USD) is an issue, but current sequence yields
(R9.4 – up to 10 Gb) make it feasible to multiplex (up to 12
samples) and it may be possible to reuse flow cells in the
future. In a recent study, we demonstrated the potential of
MinION sequencing for diagnostics, achieving pathogen iden-
tification and antibiotic resistance profiling directly from clin-
ical samples (urine) within 4 h. This included pathogen DNA
enrichment, DNA extraction, rapid library preparation
(10 min), 1 h MinION sequencing and data analysis [52].Conclusion
NGS holds great potential for improving the diagnosis and
management of TB and drug-resistant TB. WGS of MTBC
isolates is a rapid and cost effective method for molecularepidemiology and drug resistance detection, although more
work needs to be done to characterise resistance associated
mutations so that better concordance is achieved between
resistance genotype and phenotype. Shotgun metagenomics
sequencing directly from sputum for rapid diagnosis and
resistance detection is the ultimate application of NGS for
TB but is hampered by low genome coverage caused by
paucibacillary samples and competing bacterial and human
DNA. Targeted approaches, such as specifically capturing
the M. tuberculosis complex cells or DNA, and/or efficient host
DNA depletion strategies are necessary to achieve the sensi-
tivity of detection and genome coverage required.
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